No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkae481 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von B Abdi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne University, Virology Department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSER…. Hauptthemen laut MEDLINE: HIV Infections, Drug Resistance, Viral, HIV-1, Anti-HIV Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: ANRS-MIE.
Abstract (Originalsprache)
Background
Doravirine is licensed in patients living with HIV (PWH) harbouring no prior resistance to any NNRTIs. We aimed to evaluate in real life the efficacy of doravirine with prior NNRTI virological failure and NNRTI resistance-associated mutations (RAMs).
Methods
This observational study included PWH switched to a doravirine-containing regimen between 30 September 2019 and 1 May 2022, with an HIV-1 RNA of ≤50 copies/mL and past NNRTI-RAMs. The main outcome was the proportion of participants with virological failure at Week 48 and Week 96. Secondary outcomes evaluated the rate of viral suppression and transient virological blip, RAMs in the case of virological failure and side effects.
Results
A total of 102 patients were analysed, mostly men (63%), with a median age of 59 years (IQR 51–63). The median time since HIV-1 diagnosis was 26 years (IQR 16–31), on ART for 22 years (IQR 14–26) and virally suppressed for 7 years (IQR 1–11). Of the patients analysed, 25/102 (25%) had documented historical RAMs to doravirine, 9/25 (36%) showing possible resistance and 16/25 (64%) showing major resistance. The resistance profile primarily (21/23) consisted of the K103N, Y181C and/or G190A/E reverse transcriptase substitutions. Median time since the last detection of NNRTI-RAMs was 12 years (5–17). Over 2 years follow-up, no virological failure occurred, neither at Week 48 (0/87; 0%) nor Week 96 (0/86; 0%).
Conclusions
This is the first real-world study to provide new insight about the use of doravirine-containing regimens as a treatment in long-term suppressed patients whose viruses harboured specific NNRTI-RAMs in their history.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sorbonne University, Virology Department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM U1136, 75013 Paris, France.
- Sorbonne University, Infectious Diseases Department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM U1136, Paris, France.
ORCID-Profile: B Abdi, M Wirden, R Palich, V Pourcher
Förderung
- ANRS-MIE
Zitieren
APA
Abdi, B., Saliba, S., Wirden, M., Faycal, A., Cocherie, T., Palich, R., Schneider, L., Seang, S., Valantin, M. A., Pourcher, V., Calvez, V., Marcelin, A., & Katlama, C. (2025). No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae481
Vancouver
Abdi B, Saliba S, Wirden M, Faycal A, Cocherie T, Palich R, et al. No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae481
BibTeX
@article{Abdi2025,
author = {Abdi, B and Saliba, S and Wirden, M and Faycal, A and Cocherie, T and Palich, R and Schneider, L and Seang, S and Valantin, M A and Pourcher, V and Calvez, V and Marcelin, A and Katlama, C},
title = {No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkae481}
}
EUVIMED